The single institutional outcome of postoperative radiotherapy and concurrent chemoradiotherapy in resected non-small cell lung cancer
Radiation Oncology Journal 2014³â 32±Ç 3È£ p.147 ~ p.155
ÀÌȿõ(Lee Hyo-Chun) - Catholic University College of Medicine Seoul St. Mary¡¯s Hospital Department of Radiation Oncology
±è¿¬½Ç(Kim Yeon-Sil) - Catholic University College of Medicine Seoul St. Mary¡¯s Hospital Department of Radiation Oncology
¿À¼¼Áø(Oh Se-Jin) - Catholic University College of Medicine Seoul St. Mary¡¯s Hospital Department of Radiation Oncology
ÀÌ¿¬Èñ(Lee Yun-Hee) - Catholic University College of Medicine Seoul St. Mary¡¯s Hospital Department of Radiation Oncology
À̵¿¼ö(Lee Dong-Soo) - Catholic University College of Medicine Seoul St. Mary¡¯s Hospital Department of Medical Oncology
¼ÛÁøÈ£(Song Jin-Ho) - Catholic University College of Medicine Seoul St. Mary¡¯s Hospital Department of Radiation Oncology
°ÁøÇü(Kang Jin-Hyung) - Catholic University College of Medicine Seoul St. Mary¡¯s Hospital Department of Medical Oncology
¹ÚÀç±æ(Park Jae-Kil) - Catholic University College of Medicine Seoul St. Marys Hospital Department of Thoracic Surgery
Abstract
Purpose: This study was conducted to observe the outcomes of postoperative radiotherapy (PORT) with or without concurrent chemotherapy in resected non-small cell lung cancer (NSCLC) in single institution.
Materials and Methods: From 2002 to 2013, 78 patients diagnosed with NSCLC after curative resection were treated with radiotherapy alone (RT, n = 48) or concurrent chemoradiation (CCRT, n = 30). The indications of adjuvant radiation therapy were N2 node positive (n = 31), close or involved resection margin (n = 28), or gross residual disease due to incomplete resection (n = 19). The median radiation dose was 57.6 Gy (range, 29.9 to 66 Gy).
Results: Median survival time was 33.7 months (range, 4.4 to 140.3 months). The 5-year overall survival (OS) rate was 49.5% (RT 46% vs. CCRT 55.2%; p = 0.731). The 3-year disease-free survival rate was 45.5% (RT 39.4% vs. CCRT 55.3%; p = 0.130). The 3-year local control rate was 68.1% (RT 64.4% vs. CCRT 77.7%; p = 0.165). The 3-year DMFS rate was 56.1% (RT 52.6% vs. CCRT 61.7%; p = 0.314). In multivariate analysis, age ¡Ã66 years and pathologic stage III were significant poor prognostic factors for OS. Treatment failure occurred in 40 patients. Four patients had radiologically confirmed grade 3 radiation pneumonitis.
Conclusion: In NSCLC, adjuvant RT or CCRT after curative surgery is a safe and feasible modality of treatment. OS gain was seen in patients less than 66 years. Postoperative CCRT showed a propensity of achieving better local control and improved disease-free survival compared to RT alone according to our data.
Å°¿öµå
Non-small-cell lung carcinoma, Radiotherapy, Chemoradiotherapy
KMID :
1038620140320030147
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Median survival time was 33.7 months (range, 4.4 to 140.3 months). The 5-year overall survival (OS) rate was 49.5% (RT 46% vs. CCRT 55.2%; p = 0.731). The 3-year disease free survival rate was 45.5% (RT 39.4% vs. CCRT 55.3%; p = 0.130).